

# Effectiveness, safety and efficacy of INTELLiVENT–adaptive support ventilation, a closed–loop ventilation mode for use in ICU patients – a systematic review

M. Botta, E.F.E. Wenstedt, A.M. Tsonas, L.A. Buiteman-Kruizinga, D.M.P. van Meenen, H.H.M. Korsten, J. Horn, F. Paulus, A.G.J.H. Bindels, M.J. Schultz & A.J.R. De Bie

To cite this article: M. Botta, E.F.E. Wenstedt, A.M. Tsonas, L.A. Buiteman-Kruizinga, D.M.P. van Meenen, H.H.M. Korsten, J. Horn, F. Paulus, A.G.J.H. Bindels, M.J. Schultz & A.J.R. De Bie (2021) Effectiveness, safety and efficacy of INTELLiVENT–adaptive support ventilation, a closed–loop ventilation mode for use in ICU patients – a systematic review, Expert Review of Respiratory Medicine, 15:11, 1403-1413, DOI: [10.1080/17476348.2021.1933450](https://doi.org/10.1080/17476348.2021.1933450)

To link to this article: <https://doi.org/10.1080/17476348.2021.1933450>



© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



View supplementary material [↗](#)



Published online: 31 Jul 2021.



Submit your article to this journal [↗](#)



Article views: 1608



View related articles [↗](#)



View Crossmark data [↗](#)

REVIEW



## Effectiveness, safety and efficacy of INTELLiVENT–adaptive support ventilation, a closed–loop ventilation mode for use in ICU patients – a systematic review

M. Botta<sup>a,\*</sup>, E.F.E. Wenstedt<sup>b,\*</sup>, A.M. Tsonas<sup>a</sup>, L.A. Buiteman-Kruizinga<sup>a,c</sup>, D.M.P. van Meenen<sup>a</sup>, H.H.M. Korsten<sup>b,d</sup>, J. Horn<sup>a,e</sup>, F. Paulus<sup>a,f</sup>, A.G.J.H. Bindels<sup>b</sup>, M.J. Schultz<sup>a,g,h</sup> and A.J.R. De Bie<sup>b,d</sup>

<sup>a</sup>Department of Intensive Care, Amsterdam University Medical Centers, Location ‘AMC’, Amsterdam, The Netherlands; <sup>b</sup>Department of Intensive Care, Catharina Hospital Eindhoven, Eindhoven, The Netherlands; <sup>c</sup>Department of Intensive Care, Reinier de Graaf Hospital, Delft, The Netherlands; <sup>d</sup>Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands; <sup>e</sup>Amsterdam Neuroscience, Amsterdam UMC Research Institute, Amsterdam, The Netherlands; <sup>f</sup>Faculty of Health, ACHIEVE, Centre of Applied Research, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands; <sup>g</sup>Mahidol–Oxford Tropical Research Unit, Mahidol University, Mahidol–Oxford Tropical Medicine Research Unit, Bangkok, Thailand; <sup>h</sup>Nuffield Department of Medicine, University of Oxford, Oxford, UK

### ABSTRACT

**Introduction:** INTELLiVENT–Adaptive Support Ventilation (INTELLiVENT–ASV), an advanced closed–loop ventilation mode for use in intensive care unit (ICU) patients, is equipped with algorithms that automatically adjust settings on the basis of physiologic signals and patient’s activity. Here we describe its effectiveness, safety, and efficacy in various types of ICU patients.

**Areas covered:** A systematic search conducted in MEDLINE, EMBASE, the Cochrane Central register of Controlled Trials (CENTRAL), and in Google Scholar identified 10 randomized clinical trials.

**Expert opinion:** Studies suggest INTELLiVENT–ASV to be an effective automated mode with regard to the titrations of tidal volume, airway pressure, and oxygen. INTELLiVENT–ASV is as safe as conventional modes. However, thus far studies have not shown INTELLiVENT–ASV to be superior to conventional modes with regard to duration of ventilation and other patient–centered outcomes. Future studies are needed to test its efficacy.

### ARTICLE HISTORY

Received 8 January 2021  
Accepted 19 May 2021

### KEYWORDS

Artificial ventilation;  
automated ventilation;  
closed–loop ventilation;  
effectiveness; efficacy;  
intensive care unit;  
INTELLiVENT–ASV; invasive  
ventilation; protective  
ventilation; safety

## 1. Introduction



Mechanical ventilation is an often needed and at times even life–saving intervention in intensive care unit (ICU) patients. Since its introduction, various and diverse ventilation modes have found their way into clinical practice [1]. While older modes served rather simple goals, like reassuring adequate oxygenation and carbon dioxide elimination, newer modes target complex purposes like the prevention of ventilator–induced lung injury (VILI), continuous adaptation to constantly changing lung and patient conditions, weaning and even extubation readiness testing [2]. These so–called ‘closed–loop’ ventilation modes automatically adjust ventilator settings on the basis of physiologic signals and patient’s activity while using advanced algorithms that prevent the use of potentially harmful ventilator settings.

One advanced and currently commercially available closed–loop mode is named INTELLiVENT–Adaptive Support Ventilation (INTELLiVENT–ASV) (Hamilton Medical, Bonaduz, Switzerland). INTELLiVENT–ASV automatically sets and adapts nearly all ventilator settings that are usually set, or adapted by the caregiver [3–7].


Wherever and whenever a closed–loop system supports caregivers with automated interventions, three aspects are

of utmost importance – the ‘effectiveness’, the ‘safety’ and the ‘efficacy’. In the context of invasive ventilation, ‘effectiveness’ concerns the ability to reach and maintain certain ventilatory and gas exchange targets, while preventing the use of ventilator settings that are considered potentially dangerous if not injurious, in invasively ventilated ICU patients. ‘Safety’ concerns aversions of intolerable derangements in gas exchange in these often critically ill patients. ‘Efficacy’ concerns issues like improved patient–ventilator synchrony and expeditious weaning from the ventilator. Ways to measure effectiveness, safety, and efficacy include physiologic parameters like ventilation parameters, gas exchange results, and various patient–centered outcomes, such as pulmonary complications, duration of ventilation, and length of stay in ICU or hospital, or even death [8].

In 2014, three Cochrane reviews concluded that closed–loop ventilation modes could not yet be seen as more effective, but at least as safe as conventional ventilation modes for use in ICU patients [9–11]. Consequently, caregivers remained uncertain if closed–loop ventilation modes should be part of their daily ICU practice [12–14], even when they have access to such closed–loop modes on

**CONTACT** M. Botta  [m.botta@amsterdamumc.nl](mailto:m.botta@amsterdamumc.nl)  Department of Intensive Care; Amsterdam University Medical Centers, Location ‘AMC’; Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

\*authors contributed equally to the work

 Supplemental data for this article can be accessed [here](#).

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

### Article highlights

- VILI can be prevented by using a lower  $V_T$ , adequate levels of PEEP, and restrictive  $FiO_2$ ;
- Effectiveness of a ventilation mode includes  $V_T$ , PEEP and  $FiO_2$ , and levels of dysoxia;
- INTELLiVENT-ASV covers many parts of ventilation, from start of ventilation till extubation, in passive and active patients;
- INTELLiVENT-ASV is as effective as conventional ventilation in keeping  $V_T$  within lung-protective limits, and performs better than conventional ventilation with respect to time within predefined 'optimal'  $V_T$  zones;
- INTELLiVENT-ASV seems a safe mode of ventilation in critically ill patients;
- INTELLiVENT-ASV is as effective as conventional ventilation in avoiding dysoxia; and
- Studies are highly needed to test whether INTELLiVENT-ASV is superior to conventional ventilation with respect to patient-centered outcomes.

their local ventilators. Evidence for benefit of closed-loop ventilation modes, in particular of INTELLiVENT-ASV, may have increased since then, as several studies have been performed after 2014. Following a comprehensive description of typical ventilator settings that are considered important in the prevention of VILI, and a more detailed description of the closed-loop ventilation mode of interest, we present the findings of a systematic review and meta-analysis regarding the effectiveness, efficacy and safety of INTELLiVENT-ASV.

## 2. Ventilator settings

Various ventilation settings play a key role in the prevention of VILI [15]. In patients with acute respiratory distress syndrome (ARDS), and also in patients with injured lungs, a lower tidal volume ( $V_T$ ) should be considered, between 6 and 8 ml/kg predicted body weight (PBW) [16–19]. In patients without ARDS, a ventilation strategy targeting a low  $V_T$  (4–6 ml/kg PBW) may be as effective as one that targets an intermediate  $V_T$  (8–10 ml/kg PBW) [20]. The best level of positive end-expiratory pressure (PEEP) is much less certain [21], but aggressive use of higher PEEP with recruitment maneuvers has been shown to harm patients with ARDS [22]. In patients without ARDS, a lower PEEP strategy may be as efficient as a higher PEEP strategy [23]. There is increasing concern regarding a too liberal use of oxygen, or targeting too liberal oxygen levels, independent of whether a patient has ARDS or not [24,25].

Both driving pressure, the difference between the plateau pressure and PEEP, and mechanical power of ventilation, a mathematical approach that captures various ventilator settings including  $V_T$ , driving pressure, flow and respiratory rate, have an association with outcomes in patients with ARDS, as well as patients without ARDS [26–31]. While these two parameters certainly must be seen as biomarkers for existing lung injury, it could still be that simple adjustments of certain ventilator settings affect these parameters, possibly resulting in better outcomes. For instance, driving pressure could be

reduced by using a lower  $V_T$ , respiratory rate could be kept low when accepting a certain level of hypercapnia, and PEEP could be used so that atelectasis is minimized while preventing overdistension.

Based on the above, for a ventilator mode to be effective and safe, the following is usually recommended:

- use an appropriate  $V_T$  (usually between 6 and 8 ml/kg PBW), certainly in ARDS but maybe also in patients without ARDS;
- titrate PEEP and fraction of inspired oxygen ( $FiO_2$ ) by means of a lower PEEP/high  $FiO_2$  table in patients with ARDS; this approach may also fit patients without ARDS
- target a lower driving pressure; and
- avoid both hyperoxia and hyperoxemia.

## 3. INTELLiVENT-ASV

INTELLiVENT-ASV is the successor of Adaptive Support Ventilation (ASV). With both ventilation modes, the clinician inputs patient's height and gender into the ventilator for an automatic calculation of PBW. Then, ASV provides ventilation based on an operator-set minute volume if a patient is passive, or on patient's demands when a patient is or becomes active. ASV uses the so-called Otis-equation to provide the best combination of  $V_T$  and RR to have the lowest work of breathing [32]. Adjustments are done on a breath-by-breath basis, and the ventilator switches from control ventilation to assisted ventilation, or *vice versa*, when the patient becomes active or when minute ventilation becomes too low, respectively. INTELLiVENT-ASV does the same, but also uses the so-called Mead-equation to adjust  $V_T$ , RR and PEEP to reach a low driving pressure [33,34]. Furthermore, with INTELLiVENT-ASV minute volume is constantly adjusted based on continuous end-tidal carbon dioxide ( $etCO_2$ ) readings. Titrations of PEEP and  $FiO_2$  are continuously adjusted based on continuous peripheral oxygen saturation ( $SpO_2$ ) readings. For these last titrations, INTELLiVENT-ASV uses the so-called ARDS Network PEEP- $FiO_2$  tables [35,36]. The target ranges for  $etCO_2$  and  $SpO_2$  are set by the operator, in part by choosing a lung disorder (acute respiratory distress syndrome, and chronic obstructive pulmonary diseases) or a patient condition (brain injury), if present or applicable. INTELLiVENT-ASV facilitates weaning by gradually reducing minute volume and can be set to use spontaneous breathing trial by progressively reducing the ventilator settings within predefined limits, as such allowing timely identification of patients who are ready for extubation.

Thus, INTELLiVENT-ASV is able to cover nearly all parts of ventilation, from intubation and start of ventilation till extubation, and in both passive and active patients. Ventilator settings that are typically set and adjusted by the operator, like  $V_T$  and airway pressures, respiratory rate, and  $FiO_2$ , are with INTELLiVENT-ASV constantly adjusted in order to stay within predefined ranges decided by the user. It is important, though, that the user provides correct and meaningful input, like a correct body height (used by the ventilator to calculate the predicted body weight, used to determine and adjust  $V_T$ ) and

a maximum airway pressure (used by ventilator to adjust airway pressures so to stay below it). In addition, the user can adjust the limits of each setting, and can even decide to turn off one or more of the algorithms used by INTELLiVENT-ASV.

## 4. Methods

### 4.1. Systematic review

A systematic search was performed in accordance with the 'Preferred Reporting Items for Systematic reviews and Meta Analyses' (PRISMA) recommendations [35]. The search was registered at PROSPERO with registration number CRD42016046842 [36]. For the purpose of this current report, we focus on the findings regarding INTELLiVENT-ASV.

### 4.2. Search strategy

In December 2018, initial searches were conducted in MEDLINE, EMBASE, the Cochrane Central register of Controlled Trials (CENTRAL), and Google Scholar. A final search was performed in November 2020. The search strategies were developed by two authors (ADB and EW) with the help of a medical librarian using the 'Cochrane Highly Sensitive Search Strategy' [37]. No restrictions were applied on publication date or language. Reference lists of studies identified by the searches and of previously published reviews were screened for studies that may have been missed by the original searches. To identify yet unpublished or ongoing studies, we also searched the databases of the NIH National Library of Medicine, the NHS International Standard Randomized Controlled Trial Number, and the trials registry of the WHO using typical terms like 'closed-loop ventilation', 'automated ventilation', and 'automated weaning'. Full search strategy for each database is presented in **Supplement eTable 1**.

### 4.3. Study selection

Three authors (ADB, EW and MB) independently screened titles, abstracts and full texts for inclusion using the Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia; available at [www.covidence.org](http://www.covidence.org)). Parallel and crossover randomized clinical trials were selected for this systematic review and meta-analysis if the following criteria were met: (a) full-text publication available; (b) including only adult ICU patients; (c) comparing usual or standard care with INTELLiVENT-ASV; and (4) reporting effectiveness, efficacy and safety outcomes.

### 4.4. Extracted data

A form based on the data extraction format of the Cochrane Collaboration was used to extract the relevant data. Extracted information included 'study setting', 'study population', 'duration of the study', 'details of the intervention', 'details of the control strategy', 'study methodology', and 'study outcomes', next to information for the assessment of the risk of bias. Data were extracted independently by three authors (ADB, EW, or MB). Disagreements were resolved by consensus. If no

consensus was achieved, the opinion of a fourth independent reviewer (AB) was decisive. The corresponding author of an included study was contacted if the reported data considering study methods and results were incomplete or unclear.

### 4.5. Endpoints

For the purpose of this review, we used the following definitions for endpoints reflecting effectiveness, safety, and efficacy. We defined effectiveness endpoints as ventilator settings considered important for ventilation to be lung-protective, or reaching appropriate targets:

- $V_T$ ;
- PEEP;
- $FiO_2$ ;
- arterial pressure of carbon dioxide ( $PaCO_2$ );
- $etCO_2$ ;
- arterial oxygen saturation ( $SaO_2$ ); and
- $SpO_2$ .

We defined safety endpoints as:

- any reported unacceptable derangement in any ventilator parameters resulting in an immediate switch by the caregiver from INTELLiVENT-ASV to conventional ventilation;
- time spent within predefined ventilation ranges that could be seen as unsafe (when continuous data recording is available); and
- severe adverse events and adverse events related to the ventilation mode.

Efficacy endpoints were defined as outcomes frequently used in clinical studies of ventilation:

- mortality;
- length of stay in ICU;
- duration of ventilation;
- reintubation rate; and
- need for non-invasive ventilation after extubation.

### 4.6. Risk of bias and study quality

The Cochrane Collaboration's tool for assessing risk of bias was used by three authors (ADB, EW and MB) to independently assess the risk of bias for the included studies. The tool contains seven evidence-based domains including selection bias, performance bias, detection bias, attrition bias and reporting bias [38]. An independent fourth reviewer (AB) assisted to acquire consensus in case of disagreement.

### 4.7. Synthesis of results

Review Manager version 5.3 (RevMan 5.3, The Cochrane Collaboration) was used for the quantitative analysis [39], restricted to patient-centered outcomes. If outcomes were

judged to be sufficiently clinically homogenous, a quantitative synthesis was performed using random-effects models and 95% confidence intervals (95% CI). Risk ratios (RR) were used for dichotomous outcomes and mean differences (MD) were used for continuous outcomes. If the mean was not available, we used the median to estimate the mean as described before [40]. The sample size, median, and interquartile range were used to calculate an approximation of the standard deviation (SD) as described before [41]. Statistical heterogeneity was assessed with the  $I^2$  test. Heterogeneity was considered as unimportant (0 to 40%), moderate (30 to 60%), substantial (50 to 90%), or considerable (75 to 100%) [37].

## 5. Results

### 5.1. Search results

The individual searches identified 2664 articles; 1172 articles were found in PubMed, 924 in MEDLINE, 50 articles in the Cochrane library, and 518 in Google Scholar. After removing duplicates, and screening for eligibility, 10 studies remained for the current analysis [42–51] (Figure 1).

The searches in trial registries identified 10 other studies; seven studies were completed but yet unpublished, three studies were still ongoing. Data of these 10 studies were not available for this review.

### 5.2. Study characteristics

Study characteristics are presented in Table 1. Of a total of 10 studies, six were parallel randomized trials [43,45–47,49,51], and four were randomized crossover trials [42,44,48,50].




Figure 1. Search results.

INTELLiVENT–ASV was compared to its predecessor ASV in 2 studies [42,45], to pressure controlled or pressure support ventilation in five studies [44,46,48–50], and to volume-controlled ventilation or synchronized intermittent mandatory ventilation in 3 studies [43,47,51]. Four studies considered patients receiving postoperative ventilation in an ICU [43,45,47,51]; the other studies included mixed ICU populations including but not limited to patients with ARDS, patients with sepsis and patients with shock [42,44,46,49,50]. In one study, inclusion was restricted to patients with severe traumatic brain injury [48].

### 5.3. Risk of bias

Complete assessment of risk of bias per study is presented in Figure 2. Since blinding of personnel was not possible in the studies, due to the nature of the intervention, risk of performance bias was high in all studies. In five out of six parallel randomized trials, risk of selection bias was avoided through randomization with allocation concealment [43,46,47,49,51]. In the randomized crossover trials, risk of specific study design-related bias was low.

### 5.4. Effectiveness of INTELLiVENT–ASV (Table 2)

Eight studies reported on  $V_T$  [42–44,46,47,49–51]. Use of INTELLiVENT–ASV resulted in a lower  $V_T$  in three studies [42,43,51], a similar  $V_T$  in three studies [46,49,50], and higher  $V_T$  in one study [44]. INTELLiVENT–ASV was able to keep  $V_T \leq 8$  ml/kg PBW in four studies [43,46,49,51] and  $< 9$  ml/kg PBW in two studies [42,44]. Only one study [50] reported a  $V_T$  of 10 ml/kg PBW in both groups. Median  $V_T$  with INTELLiVENT–ASV was  $< 8$  ml/kg PBW in the ARDS patients [42]. In two studies, the percentage of time with  $V_T$  in a predefined ‘optimal’ range of between 6 and 10 ml/kg PBW, or  $\leq 8$  ml/kg PBW, was higher with INTELLiVENT–ASV [46,51].

Seven studies reported on PEEP and  $FiO_2$  [42–44,46,49–51]. Use of INTELLiVENT–ASV resulted in higher PEEP in two studies [46,51], similar PEEP in four studies [43,44,49,50], and lower PEEP in one study [42]. Median PEEP was higher in patients with ARDS compared to patients without ARDS [42]. INTELLiVENT–ASV used a lower  $FiO_2$  in three studies [42,43,51], but a similar  $FiO_2$  in three other studies [44,46,49].

Eight studies reported on  $SpO_2$  or  $SaO_2$  [42–44,46,47,49–51]. With INTELLiVENT–ASV, oxygenation was similar in two studies [46,47], and lower in five studies [42–44,50,51].  $SpO_2$  and  $SaO_2$  were  $< 96\%$  in three studies [42,46,50]. Hyperoxemia occurred less often with INTELLiVENT–ASV in two studies [43,49], and  $SpO_2$  was more often in a predefined ‘optimal’ zone with INTELLiVENT–ASV in two studies [46,51].

Six studies reported on  $PaCO_2$  [42–44,47,48,51], and seven on  $etCO_2$  [43,44,46–49,51]. With INTELLiVENT–ASV,  $PaCO_2$  was higher in three studies [42,43,51], and similar in three studies [44,47,48]. INTELLiVENT–ASV kept  $PaCO_2$  within normal ranges in all studies. With INTELLiVENT–ASV,  $etCO_2$  was similar to that with conventional ventilation in four studies [44,47–49], lower in one study [46], but higher in two other studies [43,51]. The percentage of time with  $etCO_2$  in an ‘optimal’ or ‘acceptable’



Table 1. Study Characteristics.

Authors	Ref	Design	N	Patients	Duration of the intervention	Control mode	Reported endpoints
Arnal <i>et al.</i> (2012)	42	randomized crossover trial	50	critically ill patients (38% normal lung, 62% ARDS)	4 hours (2 hours on each mode)	ASV	Effectiveness: $V_T^a$ , PEEP, $FiO_2$ , $SpO_2^a$ , $PaCO_2$ ; Safety: premature interruptions
Lellouche <i>et al.</i> (2013)	43	randomized clinical trial	60	patients after cardiac surgery	4 hours	CMV/PSV	Effectiveness: $V_T^b$ , PEEP, $FiO_2$ , $SpO_2$ , $PaCO_2$ , $etCO_2^b$ ; Safety: premature interruptions, time within unsafe ventilation ranges; Efficacy: ICU mortality, reintubation rate, need for NIV, duration of weaning
Clavieras <i>et al.</i> (2013)	44	randomized crossover trial	14	critically ill patients (36% peritonitis, 29% pneumonia, 14% liver transplant)	48 hours (24 hours on each mode)	PSV	Effectiveness: $V_T^a$ , PEEP <sup>a</sup> , $FiO_2^a$ , $SpO_2^a$ , $PaCO_2$ , $etCO_2^a$ ; Safety: premature interruptions
Beijers <i>et al.</i> (2014)	45	randomized clinical trial	128	patients after cardiac surgery	Inclusion to extubation $0.14 \pm 0.05$ days <sup>c</sup>	ASV, PCV/PSV	Safety: premature interruptions; Efficacy: ICU mortality, hospital mortality, ICU length of stay, reintubation rate, need for NIV, duration of weaning
Bialais <i>et al.</i> (2016)	46	randomized clinical trial	80	patients after surgery (19%), critically ill patients (30% ARDS, 14% pneumonia, 11% sepsis)	48 hours	PAC/PSV	Effectiveness: $V_T^a$ , PEEP <sup>a</sup> , $FiO_2^a$ , $SpO_2^a$ , $etCO_2^a$ ; Safety: premature interruptions, time within unsafe ventilation ranges; Efficacy: ICU mortality, hospital mortality, ICU length of stay, duration of ventilation
Fot <i>et al.</i> (2017)	47	randomized clinical trial	40	patients after cardiac surgery	Inclusion to extubation $0.13$ [0.08–0.21] days <sup>c</sup>	SIMV + protocol. weaning	Effectiveness: $V_T$ , $PaCO_2$ , $etCO_2$ ; Safety: premature interruptions, time within unsafe ventilation ranges; Efficacy: ICU length of stay, reintubation rate, duration of weaning
Anan'ev <i>et al.</i> (2017)	48	randomized crossover trial	12	patients with severe isolated traumatic brain injury	24 h (12 h on each mode)	P-CMV	Effectiveness: $PaCO_2$ , $etCO_2$
Arnal <i>et al.</i> (2018)	49	randomized clinical trial	60	critically ill patients (37% shock, 32% acute respiratory failure, 20% chronic respiratory failure exacerbation)	Inclusion to extubation/death $6.0$ [3.0–8.0] days <sup>c</sup>	VAC/PSV	Effectiveness: $V_T$ , PEEP, $FiO_2$ , $SpO_2$ , $etCO_2$ ; Efficacy: ICU mortality, 28 days mortality, ICU length of stay, need for NIV, duration of ventilation, duration of weaning
Chelly <i>et al.</i> (2020)	50	randomized crossover trial	265	critically ill patients (52% acute respiratory failure, 25% coma, 7% cardiac arrest)	During DNP + 30 min before DNP per each mode	VCV/ BIPAP/PSV	Effectiveness: $V_T$ , PEEP, $SpO_2$ ; Safety: SAEs (accidental extubation, bradycardia, cardiac arrest), premature interruptions, time within unsafe ventilation ranges
De Bie <i>et al.</i> (2020)	51	randomized clinical trial	220	patients after cardiac surgery	Inclusion to extubation $0.24 \pm 0.17$ days <sup>c</sup>	VCV/PSV	Effectiveness: $V_T^a$ , PEEP <sup>a</sup> , $FiO_2^a$ , $SpO_2^a$ , $etCO_2^a$ ; Safety: premature interruptions, time within unsafe ventilation ranges; Efficacy: ICU mortality, hospital mortality, ICU length of stay, reintubation rate, need for NIV, duration of ventilation, duration of weaning

<sup>a</sup> = ventilation parameter registered breath by breath; <sup>b</sup> = ventilation parameters continuously monitored by an operator; <sup>c</sup> = duration of ventilation in the INTELLiVENT-ASV group expressed by median [interquartile range] or mean  $\pm$  standard deviation; ARDS = acute respiratory distress syndrome; DNP = daily nursing procedure; ASV = adaptive support ventilation; CMV = controlled mechanical ventilation; PSV = pressure support ventilation; PCV = pressure-controlled ventilation; PAC = pressure assist control; SIMV = synchronized intermittent mandatory ventilation; P-CMV = pressure-controlled mechanical ventilation; VAC = volume assist control; BIPAP = biphasic positive airway pressure; VCV = volume controlled ventilation;  $V_T$  = tidal volume; PEEP = positive end-expiratory pressure;  $FiO_2$  = fraction of inspired oxygen;  $SpO_2$  = arterial oxygen saturation;  $PaCO_2$  = partial pressure of carbon dioxide;  $etCO_2$  = end-tidal carbon dioxide;  $SpO_2$  = peripheral oxygen saturation; SAEs = serious adverse events.

range was higher with INTELLiVENT-ASV in one study [51] and similar in another study [46].

### 5.5. Safety of INTELLiVENT-ASV

Five studies reported on the necessity to switch to conventional mode due to unacceptable derangement in any ventilation parameters [42–45,50]. INTELLiVENT-ASV did not affect this endpoint.

Five studies reported on time spent within predefined unsafe ventilation ranges [43,46,47,50,51]. The predefined

ventilation parameter of interest and the ranges varied between studies and are reported in Table 3. No difference was observed between INTELLiVENT-ASV and conventional ventilation in two studies [46,47], with the exception of one ventilation parameter [46], while in three studies patients ventilated with INTELLiVENT-ASV spent less time within predefined unsafe ventilation ranges compared to conventional ventilation [43,50,51].

Only one study reported severe adverse events [50]. INTELLiVENT-ASV did not have more severe adverse events related to invasive ventilation compared to conventional ventilation.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Anan 2017	?	?	+	?	+	?	+
Arnal 2012	?	+	+	?	+	+	+
Arnal 2018	+	+	+	?	+	+	+
Beijers 2014	+	+	+	?	?	+	+
Bialais 2016	+	+	+	?	+	+	+
Chelly 2020	+	?	+	?	+	+	+
Clavieras 2013	+	?	+	?	?	+	+
De Bie 2020	+	+	+	+	?	+	+
Fot 2017	+	+	+	?	+	+	?
Lellouche 2013	+	+	+	?	+	+	+

Figure 2. Assessment risk of bias.

### 5.6. Efficacy of INTELLiVENT-ASV (Table 4, Figures 3 and 4)

Four studies reported ICU mortality [43,46,49,51], one hospital mortality [46], one 28-day mortality [49], and one 30-day mortality [51]. Patients ventilated with INTELLiVENT-ASV had a lower hospital mortality in one study [46].

Three studies reported duration of invasive ventilation [46,49,51]. INTELLiVENT-ASV did not affect duration of ventilation, neither in the individual studies nor in the pooled analysis. Five studies reported duration of weaning [43,45,47,49,51]. INTELLiVENT-ASV did not affect duration of weaning, neither

in the individual studies, nor in pooled analysis. Duration of stay in the ICU was not affected by INTELLiVENT-ASV, as was reported by five studies [45-47,49,51]. Four studies reported reintubation rates [43,45,47,51], and three studies reported use of NIV after extubation [43,45,51]. INTELLiVENT-ASV neither affected reintubation rates nor need for NIV after extubation.

## 6. Discussion

### 6.1. Summary of findings

The findings of this systematic review and meta-analysis including 10 randomized clinical trials can best be summarized as follows: 1) INTELLiVENT-ASV is at least as effective as conventional ventilation in keeping  $V_T$  low and in avoiding dysoxia; 2) INTELLiVENT-ASV seems as safe as conventional ventilation; and 3) thus far, randomized clinical trials failed to show superiority of INTELLiVENT-ASV regarding efficacy.

### 6.2. Strengths of this systematic review

This review has several strengths. The systematic search was performed in accordance with the PRISMA recommendations, and was registered in PROSPERO. We used predefined endpoints, covering three important aspects – effectiveness, efficacy and safety. We reduced the risk of publication bias by not using any language restriction. The search for ongoing randomized clinical trial identified several additional studies, albeit that we could not use their data.

### 6.3. Effectiveness

$V_T$  was lower, or at least similarly low with INTELLiVENT-ASV in six out of seven studies where median or mean  $V_T$  was reported, and almost always within the limits of what is called lung-protective. Only in one study  $V_T$  was 10 ml/kg PBW in both groups, which could probably have been due to pain and discomfort during mobilization. Of note, INTELLiVENT-ASV rapidly switches from control ventilation to assisted ventilation in case a patient becomes active. With assisted ventilation there is much less control over  $V_T$ , and since lung size can increase, usually  $V_T$  increases at similar pressures – consequently,  $V_T$  could increase with INTELLiVENT-ASV while pressures remain low. Interestingly, in studies that reported time during which  $V_T$  was within predefined ‘optimal’ zones, INTELLiVENT-ASV performed better than conventional ventilation.

With INTELLiVENT-ASV,  $SpO_2$  or  $SaO_2$  are lower or at least similar, often at a lower  $FiO_2$  but with similar levels of PEEP. INTELLiVENT-ASV seems effective in preventing hyperoxemia by continuously aiming at the oxygenation target set by the physician, and thus reducing  $FiO_2$  when the target has been reached. INTELLiVENT-ASV is programmed to use a lower PEEP/higher  $FiO_2$  table when the oxygenation targets are not yet reached, but a higher PEEP/lower  $FiO_2$  table when these targets have been reached. Consequently, INTELLiVENT-ASV tends to use higher PEEP. However, in the studies included in this review, PEEP was only higher in ARDS patients [42].

Table 2. Effectiveness of INTELLiVENT-ASV.

Author	Ref.	V <sub>T</sub> , mL/Kg PBW	PEEP, cmH <sub>2</sub> O	FiO <sub>2</sub> , %	SpO <sub>2</sub> /SaO <sub>2</sub> , %	PaCO <sub>2</sub> /etCO <sub>2</sub> , mmHg
Arnal <i>et al.</i> (2012)	42	8.1 [7.7–8.6] vs 8.3 [7.8–9.0]**	8 [5–10] vs 10 [6–14]*	30 [30–39] vs 40 [30–50]**	96 [93–98] vs 97 [95–98] <sup>ab</sup>	37 [33–49] vs 37 [34–42]** <sup>c</sup>
Lellouche <i>et al.</i> (2013)	43	7.8 ± 0.5 vs 10.1 ± 1.3**	5 (5–10) vs 5 (5–8)	33 ± 6 vs 47 ± 10**	97 (93–99) vs 99 (92–99) <sup>ab</sup>	41 ± 4 vs 37 ± 4** <sup>c</sup> 38 ± 3 vs 33 ± 5** <sup>d</sup>
Clavieras <i>et al.</i> (2013)	44	8.4 [7.9–8.6] vs 7.6 [6.6–9.0]*	5.4 [5.0–7.8] vs 7.8 [5.0–9.7]	31 [30–32] vs 33 [30–41]	96 [95–97] vs 98 [97–99] <sup>a</sup> 95 (92–99) vs 98 (95–99) <sup>ab</sup>	40.5 (36–44.5) vs 41.3 (37–48.5) <sup>c</sup> 37.8 [34.5–39.5] vs 38.5 [34.3–41.2] <sup>d</sup>
Beijers <i>et al.</i> (2014)	45	-	-	-	-	-
Bialais <i>et al.</i> (2016)	46	7.9 [7.6–8.2] vs 7.5 [7.1–8.1]	7 [7–9] vs 6 [6–8]*	33 [34–42] vs 36 [33–44]	95 ± 2 vs 96 ± 2 <sup>a</sup>	36 ± 7 vs 40 ± 8 <sup>d</sup>
Fot <i>et al.</i> (2017)	47	-	-	-	99 [97–99] vs 99 [97–100] <sup>a</sup>	38 [37–42] vs 36 [32–40] <sup>c</sup> 38 [35–40] vs 37 [32–38] <sup>d</sup>
Anan'ev <i>et al.</i> (2017)	48	-	-	-	-	36 [35–37] vs 36 [34–38] <sup>c</sup> 33 [32–37] vs 34.5 [31–39] <sup>d</sup>
Arnal <i>et al.</i> (2018)	49	8.0 [7.0–8.1] vs 7.1 [7.0–9.0]	8 [5–11] vs 7 [5–9]	35 [32–42] vs 36 [32–44]	-	36 [34–40] vs 37 [33–43] <sup>d</sup>
Chelly <i>et al.</i> (2020)	50	10 ± 2 vs 10 ± 3	9 ± 3 vs 9 ± 3	-	95 ± 3 vs 96 ± 3** <sup>a</sup>	-
De Bie <i>et al.</i> (2020)	51	6.4 (5.8–6.6) vs 7.8 (7.7–8)**	6.4 (5.6–6.6) vs 5.3 (5.2–5.4)**	33 (32–44) vs 43 (41–52)**	96.6 (96–97.2) vs 97.7 (97.5–98.1)** <sup>a</sup>	42 (37–42) vs 34.5 (34–35)** <sup>d</sup>

INTELLiVENT-ASV values are presented first; data are presented as mean ± standard deviation or median [interquartile range] or median (min–max); statistically significant differences are specified by \* =  $p < 0.05$  and \*\* =  $p < 0.01$ ; <sup>a</sup> = SpO<sub>2</sub>; <sup>b</sup> = SaO<sub>2</sub>; <sup>c</sup> = PaCO<sub>2</sub>; <sup>d</sup> = etCO<sub>2</sub>; V<sub>T</sub> = tidal volume; PEEP = positive end-expiratory pressure; FiO<sub>2</sub> = fraction of inspired oxygen; SpO<sub>2</sub> = peripheral oxygen saturation; SaO<sub>2</sub> = arterial oxygen saturation; PaCO<sub>2</sub> = partial pressure of carbon dioxide; etCO<sub>2</sub> = end-tidal carbon dioxide.

Table 3. Safety of INTELLiVENT-ASV.

Author	Ref.	Ventilation parameter	Not acceptable range	Time within not acceptable range (min)	Time within not acceptable range (%)	Incidence of episodes of derangements (n/%)
Lellouche <i>et al.</i> (2013)	43	V <sub>T</sub> (ml/kg PBW)	> 12	1 ± 4 vs 15 ± 38*	0.5 vs 7.3*	-
		etCO <sub>2</sub> (mmHg)	< 25 or ≥ 51			
		Plateau pressure (cmH <sub>2</sub> O)	> 35			
		SpO <sub>2</sub> (%)	< 85			
Bialais <i>et al.</i> (2016)	46	V <sub>T</sub> (ml/kg PBW)	< 3 or > 12 <sup>a,b,c</sup>	-	1.3 (0.1–8.0) vs 0.8 (1.1–4.3)	-
		RR (breath/min)	< 10 or > 30 <sup>a</sup> < 10 or > 35 <sup>b</sup> <sup>c</sup>	-	0.9 (1.4–8.5) vs 1.7 (2.7–14.1)	-
		P <sub>max</sub> (cmH <sub>2</sub> O)	> 30 <sup>a,b,c</sup>	-	6.4 (13.3–31.6) vs 0.0 (7.1–30.4)**	-
		SpO <sub>2</sub> (%)	< 90 <sup>a,b</sup> < 83 <sup>c</sup>	-	0.5 (0.6–3.0) vs 0.7 (1.4–6.1)	-
		etCO <sub>2</sub> (mmHg)	> 55 <sup>a</sup> < 26 or > 43 <sup>b</sup> < 30 or > 65 <sup>c</sup>	-	0.0 (0.1–2.3) vs 0.1 (1.6–15.8)	-
Fot <i>et al.</i> (2017)	47	V <sub>T</sub> (ml/kg PBW)	< 6 > 10	-	-	3/17 vs 11/55 1/6 vs 5/25
		etCO <sub>2</sub> (mmHg)	< 25 > 45	-	-	5/28 vs 7/35 6/33 vs 9/45
		RR (breath/min)	> 30	-	-	3/17 vs 7/35
		SpO <sub>2</sub> (%)	< 90	-	-	0 vs 2/10
Chelly <i>et al.</i> (2020)	50	SpO <sub>2</sub> (%)	< 90 < 85	5 ± 12 vs 6 ± 11* 2 ± 6 vs 3 ± 8*	-	30/11 vs 50/19* 69/26 vs 92/35*
De Bie <i>et al.</i> (2020)	51	V <sub>T</sub> (ml/kg PBW)	> 12	-	1.5 ± 4.7 vs 3.6 ± 8.1*	23,710/4.7 vs 38,929/7.3** <sup>d</sup>
		P <sub>max</sub> (cmH <sub>2</sub> O)	≥ 36			
		etCO <sub>2</sub> (mmHg)	< 25 or ≥ 51			
		SpO <sub>2</sub> (%)	< 85			

INTELLiVENT-ASV values are presented first; data are presented as mean ± standard deviation or median (95% confidence interval for the mean); statistically significant differences are specified by \* =  $p < 0.05$  and \*\* =  $p < 0.01$ ; V<sub>T</sub> = tidal volume; etCO<sub>2</sub> = end-tidal carbon dioxide; SpO<sub>2</sub> = peripheral oxygen saturation; RR = respiratory rate; P<sub>max</sub> = maximum airway pressure; <sup>a</sup> = normal lungs/ARDS; <sup>b</sup> = brain injury; <sup>c</sup> = chronic hypercapnia; <sup>d</sup> = number of breaths.

INTELLiVENT-ASV adjusts V<sub>T</sub>, RR and PEEP to reach a lower driving pressure. Driving pressure was frequently not reported in the reviewed studies. Future studies can focus on, or at least report this parameter.

#### 6.4. Safety

The variability in definitions of unsafe ventilation ranges makes a synthesis of the results regarding safety

challenging. INTELLiVENT-ASV seems at least as safe as conventional ventilation in all studies. However, in one study [46] P<sub>max</sub> was more often in the unsafe range with INTELLiVENT-ASV than with conventional ventilation, but no statistical difference was observed in the mean P<sub>max</sub> between the two groups. Although this was not confirmed by a more recent study on post-cardiac surgery patients [51], it requires further attention in future studies.



Table 4. Efficacy of INTELLiVENT-ASV.

Author	Ref.	ICU mortality (%)	Hospital/28-day/30-day mortality (%)	ICU length of stay (days)	Reintubation rate (%)	Need for NIV (%)	Duration of ventilation (days)	Duration of weaning (days)
Arnal <i>et al.</i> (2012)	42	-	-	-	-	-	-	-
Lellouche <i>et al.</i> (2013)	43	0 vs 0	-	-	0 vs 0	0 vs 0	-	0.22 [0.18–0.31] vs 0.28 [0.2–0.36]
Clavieras <i>et al.</i> (2013)	44	-	-	-	-	-	-	-
Beijers <i>et al.</i> (2014)	45	1 vs 0	1 vs 0	0.14 [0.1–0.16] vs 0.13 [0.09–0.17]	0 vs 0	0 vs 0	-	0.14 ± 0.05 vs 0.15 ± 0.12
Bialais <i>et al.</i> (2016)	46	21 vs 29	3 vs 18 <sup>a</sup>	11.5 [10.8–20.8] vs 13.0 [11.6–24.3]	-	-	5.5 [6.0–13.0] vs 8.0 [6.5–15.3]	-
Fot <i>et al.</i> (2017)	47	-	-	2 [1.0–3.0] vs 1 [1.0–3.0]	0 vs 0	-	-	3.2 [1.9–5.2] vs 3.3 [2.6–4.2]
Anan'ev <i>et al.</i> (2017)	48	-	-	-	-	-	-	-
Arnal <i>et al.</i> (2018)	49	30 vs 23	30 vs 23 <sup>b</sup>	10.0 [6.0–13.0] vs 9.0 [5.0–14.0]	-	-	6.0 [3.0–9.0] vs 6.5 [4.0–14.5]	4.0 [1.0–5.5] vs 2.0 [1.0–4.0]
Chelly <i>et al.</i> (2020)	50	-	-	-	-	-	-	-
De Bie <i>et al.</i> (2020)	51	2.8 vs 0	2.8 vs 0 <sup>c</sup>	0.3 [0.3–0.6] vs 0.4 [0.3–0.7]	1.9 vs 1.9	1.9 vs 7.2	0.2 [0.14–0.3] vs 0.21 [0.14–0.33]	0.11 [0.04–0.09] vs 0.11 [0.05–0.23]

INTELLiVENT-ASV values are presented first; data are presented as mean ± standard deviation or median [interquartile range] or median (95% confidence interval for the mean); statistically significant differences are specified by \* =  $p < 0.05$  and \*\* =  $p < 0.01$ ; <sup>a</sup> = hospital mortality; <sup>b</sup> = 28-day mortality; <sup>c</sup> = 30-day mortality; ICU = intensive care unit; NIV = non-invasive ventilation.




Figure 3. Forest plot of duration of mechanical ventilation.




Figure 4. Forest plot of duration of weaning.

Once INTELLiVENT-ASV has reached the oxygenation target, the algorithm follows the higher PEEP/lower FiO<sub>2</sub> table with the purpose of avoiding alveolar de-recruitment. It is questionable if this approach is beneficial for all patients as, thus far, randomized clinical trials failed to show clinical benefit of a higher PEEP over a lower PEEP strategy [52–54], and one study even showed harm of using a higher PEEP strategy in patients with ARDS [22]. Of note, INTELLiVENT-ASV allows

the clinician to decide the maximum level of PEEP that can be used by setting an upper limit for this parameter.

### 6.5. Efficacy

Thus far, most studies of INTELLiVENT-ASV have been too small to allow firm conclusions regarding the efficacy of INTELLiVENT-ASV. Also, studies used various populations,

ranging from critically ill patients with ARDS who need complex ventilation that is usually needed for days, to patients receiving simple postoperative ventilation that is usually applied for only hours. Also, the outcomes used varied substantially between the studies.

Sufficiently sized studies are highly needed. As of late 2020, we are aware of at least two sufficiently sized randomized clinical trials, i.e., 'EASiVENT' (NCT04400643), a multicenter international study in the US, France and Switzerland, with the objective of evaluating the efficacy and safety of INTELLiVENT-ASV in an adult ICU population, and 'ACTIVE' (NCT04593810), a multicenter international study in the Netherlands and Italy, with the objective to compare the number of ventilator-free days and alive at day 28 and the quality of breathing between INTELLiVENT-ASV and conventional ventilation. Of note, INTELLiVENT-ASV is commercially available in many countries, but, for example, not yet in the United States of America.

### 6.6. Limitations of this systematic review

This review has limitations. First, besides randomized clinical trials, it included four crossover trials, lowering the level of evidence. However, crossover designs also have the advantage of eliminating between-participant variations. As these studies did evaluate safety and effectiveness, we would have missed important information if we had excluded them from this review. Second, though other automated modes are currently available for use in critically ill patients, we restricted the analysis to INTELLiVENT-ASV in order to get homogeneity of the studied intervention and because INTELLiVENT-ASV is currently the most advanced and complete mode of ventilation – indeed, in contrast to other automated modes, INTELLiVENT-ASV works under all conditions, i.e., not only during the weaning phase when a patient becomes active, but also in passive patients. Third, we restricted this review to studies in adult patients, and none of the studies reported on 'special' conditions or situations, like one-lung ventilation, or ventilation in transplant patients. Fourth, we did not report other outcomes that could also be affected by INTELLiVENT-ASV, like duration of spontaneous breathing, and patient-ventilator asynchronies, due to lack of studies on these topics. Fifth, heterogeneity in studied cohorts and duration of the intervention hampers generalizability. Last but not least, one major limitation of all included studies was the impossibility of blinding patients and personnel due to the nature of the intervention. This leads to high risk of performance bias and the Hawthorne effect, which usually cannot be avoided in studies of ventilation in critically ill patients.

## 7. Conclusion

In conclusion, INTELLiVENT-ASV is an effective and safe fully closed-loop ventilation mode with regard to  $V_T$  and oxygenation titrations, but thus far the randomized clinical trials failed to show superiority in respect of efficacy. Future studies are needed to test the effects of INTELLiVENT-ASV on patient-centered endpoints.

## 8. Expert opinion

In this review, we brought together the available evidence for effectiveness, safety and efficacy of INTELLiVENT-ASV. The effectiveness and safety of this automated mode of ventilation are at least comparable to conventional ventilation; the randomized clinical trials reported thus far, however, failed to show superiority in respect of efficacy. The actual search adds to the literature as it focuses exclusively on one automated mode of invasive ventilation and by selecting high-quality studies.

Randomized clinical trials of INTELLiVENT-ASV, using clinically relevant patient-centered outcomes, are currently being performed. These and other studies will show whether or not INTELLiVENT-ASV has the potential to improve outcomes of critically ill patients, i.e., duration of mechanical ventilation and duration of weaning. A reduction in duration of ventilation, on its part, could affect multiple secondary clinical endpoints, such as length of ICU and hospital stay, ICU-acquired weakness and mechanical ventilation complications, e.g., ventilator-associated pneumonia or barotrauma. Moreover, a reduction in duration of ventilation could also affect economical endpoints, making this mode of ventilation relevant for daily practice, both from a patient and a healthcare-efficiency perspective.

Future studies could also address the impact of INTELLiVENT-ASV on other important ventilation subjects in both ARDS and non-ARDS patients, i.e., mechanical power and driving pressure, which together reflect the 'intensity of ventilation', and patient-ventilator asynchronies.

Several studies of INTELLiVENT-ASV showed a reduction in required interactions with the ventilator, meaning that use of INTELLiVENT-ASV could reduce workload. While especially of interest during the current coronavirus disease 2019 pandemic during which many patients need ventilatory support, any reduction in workload of ICU doctors and nurses should be embraced at all times, as many studies have shown a correlation between workload and ICU mortality.

Utilizing automated modes of ventilation, like INTELLiVENT-ASV, requires healthcare workers to provide correct inputs, to set target ranges for  $SpO_2$  and  $etCO_2$ , and to leave settings that are usually set by healthcare workers to the ventilator. This is very different from how non-automated modes are used. This change in interaction can be a real challenge for healthcare workers. Not surprisingly, therefore, automated modes like INTELLiVENT-ASV could cause resistance from experienced healthcare workers. In a highly-controlled environment like an ICU, it could be difficult to 'entrust' a delicate process like lung-protective ventilation to a set of algorithms within a ventilator, a phenomenon also known as the 'black box effect'. This aspect of automated ventilation can be a bigger obstacle to its implementation than trusting that it could be as safe and effective as non-automated ventilation.

It should be noted that algorithms used in automated modes of ventilation can and must change with the appearance of evidence for benefit or harm of certain settings – for instance, it is highly uncertain whether the use of a higher PEEP level really yields clinical benefit. If this is not the case,

the algorithms should be changed so that the use of a higher PEEP is prevented. In other words, updates are required – with every new piece of evidence coming in.

## Abbreviations

ARDS: acute respiratory distress syndrome  
 ASV: Adaptive Support Ventilation  
 ICU: intensive care unit  
 etCO<sub>2</sub>: end-tidal carbon dioxide  
 FiO<sub>2</sub>: fraction of inspired oxygen  
 MD: mean differences  
 PBW: predicted body weight  
 PEEP: positive end-expiratory pressure  
 PRISMA: Preferred Reporting Items for Systematic reviews and Meta Analyses  
 RR: Risk ratios  
 SaO<sub>2</sub>: arterial oxygen saturation  
 SpO<sub>2</sub>: pulse oximetry saturation  
 V<sub>T</sub>: tidal volume  
 VILI: ventilator-induced lung injury

## Acknowledgments

Manuscripts in Chinese were translated to English by Shan Nan (College of Biomedical Engineering and Instrumental Science, Zhejiang University, Hangzhou, China).

## Funding

This paper was not funded.

## Declaration of interest

E. Korsten has been a clinical consultant for Philips Research since January 2016. A. de Bie's PhD research is funded by the Impuls-2 project, a collaboration of Catherina Hospital Eindhoven, Eindhoven University of Technology and Philips Research. M.J. Schultz (in 2018) and A. de Bie (in 2015, 2017 and 2018) participated in workshops organized by Hamilton Medical to learn the principles of INTELLIVENT-ASV. The travel expenses were paid by Hamilton Medical. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

## Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

## References

Papers of special note have been highlighted as either of interest (\*) or of considerable interest (\*\*) to readers.

- Kacmarek RM. The mechanical ventilator: past, present, and future. *Respir Care*. 2011 Aug;56(8):1170–1180.
- Platen PV, Pomprapa A, Lachmann B, et al. The dawn of physiological closed-loop ventilation-a review. *Crit Care*. 2020 Mar 29;24(1):121.
- Wysocki M, Jouvet P, Jaber S. Closed loop mechanical ventilation. *J Clin Monit Comput*. 2014 Feb;28(1):49–56.
- Chatburn RL, El-Khatib M, Mireles-Cabodevila E. A taxonomy for mechanical ventilation: 10 fundamental maxims. *Respir Care*. 2014 Nov;59(11):1747–1763.
- Mireles-Cabodevila E, Hatipoğlu U, Chatburn RL. A rational framework for selecting modes of ventilation. *Respir Care*. 2013 Feb;58(2):348–366.
- Chatburn RL, Mireles-Cabodevila E. Closed-loop control of mechanical ventilation: description and classification of targeting schemes. *Respir Care*. 2011 Jan;56(1):85–102.
- Branson RD. Automation of Mechanical Ventilation. *Crit Care Clin*. 2018 Jul;34(3):383–394.
- Burches EBM. Efficacy, Effectiveness and Efficiency in the Health Care: the Need for an Agreement to Clarify its Meaning, *Int Arch Public Health Community Med*, 2020
- Burns KE, Lellouche F, Lessard MR, et al. Automated weaning and spontaneous breathing trial systems versus non-automated weaning strategies for discontinuation time in invasively ventilated post-operative adults. *Cochrane Database Syst Rev*. 2014 Feb;13(2):CD008639.
- Burns KE, Lellouche F, Nisenbaum R, et al. Automated weaning and SBT systems versus non-automated weaning strategies for weaning time in invasively ventilated critically ill adults. *Cochrane Database Syst Rev*. 2014 9;Sep(9):CD008638.
- Rose L, Schultz MJ, Cardwell CR, et al. Automated versus non-automated weaning for reducing the duration of mechanical ventilation for critically ill adults and children. *Cochrane Database Syst Rev*. 2014 Jun;10(6):CD009235.
- Wenstedt EFE, AJR DBD, Roos AN, et al. Current practice of closed-loop mechanical ventilation modes on intensive care units - a nationwide survey in the Netherlands. *Neth J Med*. 2017 May;75(4):145–150.
- Rose L, Blackwood B, Egerod I, et al. Decisional responsibility for mechanical ventilation and weaning: an international survey. *Crit Care*. 2011;15(6):R295. .
- Pylypenko MM. Current practice of mechanical ventilation: preliminary results of national survey in ukraine. *Intensive Care Medicine*. 2013;201–539.
- Slutsky AS, Ranieri VM. Ventilator-induced lung injury. *N Engl J Med*. 2013 Nov 28;369(22):2126–2136.
- Brower RG, Fessler HE. Mechanical ventilation in acute lung injury and acute respiratory distress syndrome. *Clin Chest Med*. 2000 Sep;21(3):491–510. viii
- Esteban A, Frutos-Vivar F, Muriel A, et al. Evolution of mortality over time in patients receiving mechanical ventilation. *Am J Respir Crit Care Med*. 2013 Jul 15;188(2):220–230.
- Lee PC, Helmsmoortel CM, Cohn SM, et al. Are low tidal volumes safe? *Chest*. 1990 Feb;97(2):430–434. .
- Determann RM, Royakkers A, Wolthuis EK, et al. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: a preventive randomized controlled trial. *Crit Care*. 2010;14(1):R1. .
- Simonis FD, Serpa Neto A, Binnekade JM, et al. Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS: a Randomized Clinical Trial. *Jama*. 2018 Nov 13;320(18):1872–1880.
- Serpa Neto A, Filho RR, Cherpanath T, et al. Associations between positive end-expiratory pressure and outcome of patients without ARDS at onset of ventilation: a systematic review and meta-analysis of randomized controlled trials. *Ann Intensive Care*. 2016 Dec;6(1):109. .
- Cavalcanti AB, Suzumura ÉA, Laranjeira LN, et al. Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: a Randomized Clinical Trial. *Jama*. 2017 Oct 10;318(14):1335–1345.
- Algera AG, Pisani L, Serpa Neto A, et al. Effect of a Lower vs Higher Positive End-Expiratory Pressure Strategy on Ventilator-Free Days in ICU Patients Without ARDS: a Randomized Clinical Trial. *Jama*. 2020 Dec 22;324(24):2509–2520.
- Girardis M, Busani S, Damiani E, et al. Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: the Oxygen-ICU Randomized Clinical Trial. *Jama*. 2016 Oct 18;316(15):1583–1589.

25. Helmerhorst HJ, Roos-Blom MJ, van Westerloo DJ, et al. Association Between Arterial Hyperoxia and Outcome in Subsets of Critical Illness: a Systematic Review, Meta-Analysis, and Meta-Regression of Cohort Studies. *Crit Care Med*. 2015 Jul;43(7):1508–1519. .
26. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. *JAMA*. 2016 Feb 23;315(8):788–800.
27. Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med*. 2015 Feb 19;372(8):747–755.
28. Bugeo G, Retamal J, Bruhn A. Driving pressure: a marker of severity, a safety limit, or a goal for mechanical ventilation? *Crit Care*. 2017 Aug 4;21(1):199.
29. Cressoni M, Gotti M, Chiurazzi C, et al. Mechanical Power and Development of Ventilator-induced Lung Injury. *Anesthesiology*. 2016 May;124(5):1100–1108. .
30. Serpa Neto A, Deliberato RO, Johnson AEW, et al. Mechanical power of ventilation is associated with mortality in critically ill patients: an analysis of patients in two observational cohorts. *Intensive Care Med*. 2018 Nov;44(11):1914–1922. .
31. Zhang Z, Zheng B, Liu N, et al. Mechanical power normalized to predicted body weight as a predictor of mortality in patients with acute respiratory distress syndrome. *Intensive Care Med*. 2019 Jun;45(6):856–864. .
32. Otis AB, Fenn WO, Rahn H. Mechanics of breathing in man. *J Appl Physiol*. 1950 May;2(11):592–607.
33. Mead J. The control of respiratory frequency. *Ann N Y Acad Sci*. 1963 Jun;24(109):724–729.
34. Van Der Staay M, Chatburn RL. Advanced modes of mechanical ventilation and optimal targeting schemes. *Intensive Care Med Exp*. 2018 ;6(1):30. .
35. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med*. 2009 Jul 21;6(7):e1000100.
36. Wenstedt EFE, AJR DBD, Bindels AJ, et al. Safety, efficacy, and usability of intelligent full closed-loop mechanical ventilation systems in critically ill and postoperative patients on the intensive care: a systematic review and meta-analysis. *PROSPERO*2016.
37. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0. *Cochrane Collab*. 2011.
38. Higgins JPT, Sterne JAC. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions: the Cochrane Collaboration*. 2011.
39. TCC TNCC. Review Manager (RevMan). Version 5.3 ed2011.
40. Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res*. 2018 Jun;27(6):1785–1805. .
41. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol*. 2014 Dec;14(1):135. .
42. Arnal J-M, Wysocki M, Novotni D, et al. Safety and efficacy of a fully closed-loop control ventilation (IntelliVent-ASV®) in sedated ICU patients with acute respiratory failure: a prospective randomized crossover study. *Intensive Care Med*. 2012;38(5):781–787. .
43. Lellouche F, Bouchard PA, Simard S, et al. Evaluation of fully automated ventilation: a randomized controlled study in post-cardiac surgery patients. *Intensive Care Med*. 2013 Mar;39(3):463–471. .
- **This RCT demonstrated the safety of INTELLiVENT-ASV in patients after cardiac surgery and showed that INTELLiVENT-ASV was able to maintain patients within a predefined range of optimal ventilation.**
44. Clavieras N, Wysocki M, Coisel Y, et al. Prospective randomized crossover study of a new closed-loop control system versus pressure support during weaning from mechanical ventilation. *Anesthesiology* 2013 Sep;119(3):631–641. .
45. Beijers AJ, Roos AN, Bindels AJ. Fully automated closed-loop ventilation is safe and effective in post-cardiac surgery patients. *Intensive Care Med*. 2014 May;40(5):752–753. .
- **This RCT showed that INTELLiVENT-ASV was as safe and efficient as conventional ventilation and ASV in patients after cardiac surgery.**
46. Bialais E, Wittebole X, Vignaux L, et al. Closed-loop ventilation mode (IntelliVent®-ASV) in intensive care unit: a randomized trial. *Minerva Anestesiol*. 2016 Jun;82(6):657–668.
- **This RCT studied the effectiveness of INTELLiVENT-ASV in a mixed ICU population with an expected duration of mechanical ventilation of more than 48 hours.**
47. Fot EV, Izotova NN, Yudina AS, et al. Automated Weaning from Mechanical Ventilation after Off-Pump Coronary Artery Bypass Grafting. *Front Med (Lausanne)*. 2017;4:31.
- **This RCT proved the effectiveness of INTELLiVENT-ASV in patients after cardiac surgery, with no difference in efficacy compared to a protocolized weaning**
48. Anan'ev EP, Polupan AA, Matskovskiy IV, et al. [Use of the IntelliVent-ASV mode for maintaining the target EtCO<sub>2</sub> range in patients with severe TBI]. *Zh Vopr Neirokhir Im N N Burdenko*. 2017;81(5):63–68. .
49. Arnal JM, Garnero A, Novotni D, et al. Closed loop ventilation mode in Intensive Care Unit: a randomized controlled clinical trial comparing the numbers of manual ventilator setting changes. *Minerva Anestesiol*. 2018 Jan;84(1):58–67. .
- **This RCT showed a similar effectiveness and efficacy of INTELLiVENT-ASV compared to conventional ventilation in a mixed ICU population.**
50. Chelly J, Mazerand S, Jochmans S, et al. Automated vs. conventional ventilation in the ICU: a randomized controlled crossover trial comparing blood oxygen saturation during daily nursing procedures (I-NURSING). *Crit Care*. 2020 Jul 22;24(1):453.
51. AJR DB, Neto AS, van Meenen DM, et al. Fully automated post-operative ventilation in cardiac surgery patients: a randomised clinical trial. *Br J Anaesth*. 2020 Nov;125(5):739–749. .
- **This RCT showed in 220 patients after cardiac surgery a higher effectiveness of INTELLiVENT-ASV compared to conventional ventilation with regard to lung-protective ventilation with no difference in efficacy.**
52. Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med*. 2004 Jul 22;351(4):327–336.
53. Meade MO, Cook DJ, Guyatt GH, et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA*. 2008 Feb 13;299(6):637–645.
54. Mercat A, Richard JC, Vielle B, et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA*. 2008 Feb 13;299(6):646–655.